BioSpace News Archive

Deals

Bio-Techne Declares Dividend - Nov 05, 2020

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2020.

November 5, 2020
·
1 min read
Business

Aarti Shah to Retire as Lilly Chief Information and Digital Officer

Eli Lilly and Company announced that Aarti Shah, Ph.D., senior vice president and chief information and digital officer, will retire in the first half of 2021 after 27 years of service with the company.

November 5, 2020
·
3 min read
Business

Bio-Techne Releases First Quarter Fiscal 2021 Results

Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2020.

November 5, 2020
·
16 min read
Business

Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update

Synlogic ends 3Q2020 with $102.0 million in cash, cash equivalents and investments supporting projected runway into 2022

November 5, 2020
·
10 min read
Business

Regeneron Reports Third Quarter 2020 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2020 and provided a business update.

November 5, 2020
·
32 min read
Business

AmerisourceBergen Reports Fiscal 2020 Fourth Quarter and Year End Results

AmerisourceBergen Corporation reported that in its fiscal year 2020 fourth quarter ended September 30, 2020, revenue increased 7.9 percent to $49.2 billion.

November 5, 2020
·
31 min read
Deals

Merck to Acquire VelosBio

Acquisition Strengthens Merck’s Oncology Pipeline with VLS-101, an Investigational Antibody-Drug Conjugate to Treat Hematological Malignancies and Solid Tumors

November 5, 2020
·
7 min read
Business

Cardinal Health Reports First Quarter Fiscal 2021 Results

GAAP(1) operating loss was $624 million due to an incremental $1.0 billion pre-tax accrual related to opioid litigation; non-GAAP operating earnings increased 7% to $618 million

November 5, 2020
·
27 min read
Pharm Country

LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Patients Treated with LYNPARZA and Bevacizumab Lived Without Disease Progression or Death for a Median of 37.2 Months vs. 17.7 Months for Bevacizumab Alone Following Response to Platinum-Based Chemotherapy

November 5, 2020
·
22 min read
Business

Ra Medical Systems to Report Third Quarter 2020 Financial Results on November 12, 2020

Ra Medical Systems, Inc. announces that it will report third quarter 2020 financial results and provide a business update after market close on Thursday, November 12, 2020.

November 5, 2020
·
2 min read